Non-invasive markers of liver fibrosis in chronic liver disease in a group of Mexican children. A multicenter study

被引:16
|
作者
Flores-Calderon, Judith [1 ]
Moran-Villota, Segundo [1 ]
Ramon-Garcia, Guillermo [1 ]
Gonzalez-Romano, Berenice [1 ]
del Carmen Bojorquez-Ramos, Maria [2 ]
Cerdan-Silva, Laura [3 ]
Hernandez-Frias, Pablo [3 ]
机构
[1] Hosp Pediat Mexico City, Ctr Med Nacl Siglo 21, Inst Mexicano Seguro Social, Dept Gastroenterol & Anat Patol,UMAE, Mexico City 06725, DF, Mexico
[2] Hosp Pediat, Ctr Med Nacl Occidente, Dept Gastroenterol, UMAE, Guadalajara, Jalisco, Mexico
[3] Inst Mexicano Seguro Social, Ctr Med Nacl La Raza, Dept Gastroenterol, UMAE Dr Gaudencio Gonzalez Garza, Mexico City, DF, Mexico
关键词
Liver fibrosis; APRI; Fibrotest (R); Children; CHRONIC HEPATITIS-B; BIOPSY; FIBROTEST; CIRRHOSIS; INFANTS; INDEX;
D O I
10.1016/S1665-2681(19)30933-0
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Introduction. Identifying liver fibrosis is important to evaluate the severity of liver damage and to establish a prognosis. Utility of non-invasive markers of liver fibrosis has been proved in adults but there are few reports in children. The aim of this study was to evaluate Fibrotest (R) score and APRI suitability to identify children with liver fibrosis. Material and methods. 68 children with chronic liver disease requiring liver biopsy were prospectively included from three 3rd-level pediatric hospitals. The same pathologist evaluated all liver biopsies; fibrosis degree was determined by METAVIR score. Serum samples were obtained to determine Fibrotest (R) and APRI. AUROC were used to determine cut-off and differentiate between advanced fibrosis (METAVIR F3, F4) and no fibrosis (F0). Results. 68 biopsies were evaluated; METAVIR > F3 was identified in 26 (38%). Non invasive liver fibrosis markers to differentiate between advanced and no fibrosis were: Fibrotest (R) AUROC = 0.90 (95% CI 0.77-1.00) (cut-off value 0.35) sensitivity 88.00% (95% CI 68-96) and specificity 80% (95% CI 29-98); and for APRI AUROC = 0.97 (95% CI 0.92-1.00) (cut-off value 0.82), sensitivity 88% (95% CI 68-96) and specificity = 100% (95% CI 46-100). Conclusion. These results suggest the utility of Fibrotest (R) and APRI to identify advanced fibrosis; they can be recommended to select patients for liver biopsy and during patient follow-up.
引用
收藏
页码:364 / 368
页数:5
相关论文
共 50 条
  • [21] Chronic Liver Disease with Obesity: Non-invasive Risk Markers tested
    Kessing, Richard
    [J]. ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2021, 59 (03): : 190 - +
  • [22] Non-invasive markers of fibrosis in the diagnosis of non-alcoholic fatty liver disease
    Arteaga, Ingrid
    Buezo, Isabel
    Exposito, Carmen
    Pera, Guillem
    Rodriguez, Lluis
    Aluma, Alba
    Antonia Auladell, M.
    Toran, Pere
    Caballeria, Llorenc
    [J]. GASTROENTEROLOGIA Y HEPATOLOGIA, 2014, 37 (09): : 503 - 510
  • [23] CONCORDANCE OF NON-INVASIVE MARKERS OF LIVER FIBROSIS IN A MIXED POPULATION OF LIVER DISEASES
    Trembling, P. M.
    Cheung, M.
    Tanwar, S.
    Rosenberg, W. M.
    [J]. GUT, 2012, 61 : A408 - A408
  • [24] NON-INVASIVE MARKERS OF LIVER FIBROSIS IN FATTY LIVER DISEASE ARE UNRELIABLE IN PEOPLE OF SOUTH ASIAN DESCENT
    De Silva, S.
    Li, W.
    Kemos, P.
    Brindley, J.
    Mecci, J.
    Samsuddin, S.
    Chin-Aleong, J.
    Feakins, R.
    Foster, G.
    Syn, W-K
    Alazawi, W.
    [J]. GUT, 2017, 66 : A164 - A164
  • [25] Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of South Asian descent
    De Silva, Sampath
    Li, Wenhao
    Kemos, Polychronis
    Brindley, James H.
    Mecci, Jibran
    Samsuddin, Salma
    Chin-Aleong, Joanne
    Feakins, Roger M.
    Foster, Graham R.
    Syn, Wing-Kin
    Alazawi, William
    [J]. FRONTLINE GASTROENTEROLOGY, 2018, 9 (02) : 115 - 121
  • [26] ACCURACY OF NON-INVASIVE FIBROSIS MARKERS IN THE DIAGNOSIS OF ADVANCED FIBROSIS IN NONALCOHOLIC FATTY LIVER DISEASE
    Kim, Donghee
    Kim, W. Ray
    Talwalkar, Jayant A.
    Ehman, Richard
    [J]. HEPATOLOGY, 2011, 54 : 1118A - 1119A
  • [27] Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study
    Morishita, Asahiro
    Oura, Kyoko
    Takuma, Kei
    Nakahara, Mai
    Tadokoro, Tomoko
    Fujita, Koji
    Tani, Joji
    Shi, Tingting
    Himoto, Takashi
    Tatsuta, Miwa
    Moriya, Akio
    Senoo, Tomonori
    Tsutsui, Akemi
    Nagano, Takuya
    Takaguchi, Koichi
    Ono, Masafumi
    Masaki, Tsutomu
    [J]. HEPATOLOGY INTERNATIONAL, 2023, 17 (03) : 606 - 614
  • [28] Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study
    Asahiro Morishita
    Kyoko Oura
    Kei Takuma
    Mai Nakahara
    Tomoko Tadokoro
    Koji Fujita
    Joji Tani
    Tingting Shi
    Takashi Himoto
    Miwa Tatsuta
    Akio Moriya
    Tomonori Senoo
    Akemi Tsutsui
    Takuya Nagano
    Koichi Takaguchi
    Masafumi Ono
    Tsutomu Masaki
    [J]. Hepatology International, 2023, 17 : 606 - 614
  • [29] Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease
    Rosa Lombardi
    Elena Buzzetti
    Davide Roccarina
    Emmanuel A Tsochatzis
    [J]. World Journal of Gastroenterology, 2015, (39) : 11044 - 11052
  • [30] Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease
    Lombardi, Rosa
    Buzzetti, Elena
    Roccarina, Davide
    Tsochatzis, Emmanuel A.
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (39) : 11044 - 11052